Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at evading eradication ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline results from its Phase 3 ARTISTRY-1 trial for an investigational HIV ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

A rapist deliberately passed HIV to seven men when he had sex with them, a court heard. Adam Hall is on trial accused of raping four alleged victims he transmitted the virus to as well as another man, ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.